Literature DB >> 20030734

Multiple effects of amprenavir against Candida albicans.

Lys A Braga-Silva1, Sheijy S V Mogami, Roberta S Valle, Ignácio D Silva-Neto, André L S Santos.   

Abstract

Secreted aspartyl peptidases (Saps) are virulence attributes produced by Candida albicans that participate in multiple aspects of the fungal biology and pathogenesis. In the present paper, we have shown that amprenavir, a peptidase inhibitor used in HIV chemotherapy, inhibited Sap2 and growth of C. albicans and also promoted ultrastructural alterations. Esterase activity, sterol content, biofilm formation and the expression of surface mannose- and sialic acid-rich glycoconjugates were also reduced by amprenavir.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20030734     DOI： 10.1111/j.1567-1364.2009.00595.x

Source DB:  PubMed          Journal:  FEMS Yeast Res        ISSN： 1567-1356            Impact factor:   2.796


  10 in total

1.  Protease expression by microorganisms and its relevance to crucial physiological/pathological events.

Authors:  André Luis Souza Dos Santos
Journal:  World J Biol Chem       Date:  2011-03-26

2.  HIV aspartyl protease inhibitors as promising compounds against Candida albicans André Luis Souza dos Santos.

Authors:  André Luis Souza Dos Santos
Journal:  World J Biol Chem       Date:  2010-02-26

3.  Sulfone derivatives reduce growth, adhesion and aspartic protease SAP2 gene expression.

Authors:  Małgorzata Bondaryk; Zbigniew Ochal; Monika Staniszewska
Journal:  World J Microbiol Biotechnol       Date:  2014-06-01       Impact factor: 3.312

Review 4.  Aspartic peptidases of human pathogenic trypanosomatids: perspectives and trends for chemotherapy.

Authors:  L O Santos; A S Garcia-Gomes; M Catanho; C L Sodre; A L S Santos; M H Branquinha; C M d'Avila-Levy
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

5.  HIV Aspartic Peptidase Inhibitors Modulate Surface Molecules and Enzyme Activities Involved with Physiopathological Events in Fonsecaea pedrosoi.

Authors:  Vanila F Palmeira; Daniela S Alviano; Lys A Braga-Silva; Fátima R V Goulart; Marcela Q Granato; Sonia Rozental; Celuta S Alviano; André L S Santos; Lucimar F Kneipp
Journal:  Front Microbiol       Date:  2017-05-19       Impact factor: 5.640

6.  Secreted aspartyl proteinase (PbSap) contributes to the virulence of Paracoccidioides brasiliensis infection.

Authors:  Daniele Gonçalves Castilho; Alison Felipe Alencar Chaves; Marina Valente Navarro; Palloma Mendes Conceição; Karen Spadari Ferreira; Luiz Severino da Silva; Patricia Xander; Wagner Luiz Batista
Journal:  PLoS Negl Trop Dis       Date:  2018-09-27

7.  Aspartic peptidase of Phialophora verrucosa as target of HIV peptidase inhibitors: blockage of its enzymatic activity and interference with fungal growth and macrophage interaction.

Authors:  Marcela Q Granato; Ingrid S Sousa; Thabatta L S A Rosa; Diego S Gonçalves; Sergio H Seabra; Daniela S Alviano; Maria C V Pessolani; André L S Santos; Lucimar F Kneipp
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

8.  Repositioning Lopinavir, an HIV Protease Inhibitor, as a Promising Antifungal Drug: Lessons Learned from Candida albicans-In Silico, In Vitro and In Vivo Approaches.

Authors:  André L S Santos; Lys A Braga-Silva; Diego S Gonçalves; Lívia S Ramos; Simone S C Oliveira; Lucieri O P Souza; Vanessa S Oliveira; Roberto D Lins; Marcia R Pinto; Julian E Muñoz; Carlos P Taborda; Marta H Branquinha
Journal:  J Fungi (Basel)       Date:  2021-05-28

9.  Nelfinavir is effective in inhibiting the multiplication and aspartic peptidase activity of Leishmania species, including strains obtained from HIV-positive patients.

Authors:  Lívia O Santos; Bianca S Vitório; Marta H Branquinha; Conceição M Pedroso e Silva; André L S Santos; Claudia M d'Avila-Levy
Journal:  J Antimicrob Chemother       Date:  2012-10-28       Impact factor: 5.790

10.  Fonsecaea pedrosoi Sclerotic Cells: Secretion of Aspartic-Type Peptidase and Susceptibility to Peptidase Inhibitors.

Authors:  Vanila F Palmeira; Fatima R V Goulart; Marcela Q Granato; Daniela S Alviano; Celuta S Alviano; Lucimar F Kneipp; André L S Santos
Journal:  Front Microbiol       Date:  2018-06-29       Impact factor: 5.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.